全球疫苗市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

疫苗市场分析  

在预防保健意识不断增强和疫苗技术进步的推动下，全球疫苗市场正在经历强劲增长。最近的发展包括mRNA 疫苗的快速部署，尤其是在 COVID-19 大流行期间，这为未来各种传染病的疫苗开发树立了先例。这项创新技术加速了疫苗的开发时间表，并展示了提高效力和安全性的潜力。此外，正在进行的联合疫苗研究正在扩大市场，因为它可以通过一次注射对多种疾病进行免疫，从而提高患者的依从性和覆盖率。监管机构在促进新疫苗更快获批方面也发挥了关键作用，从而能够及时应对新出现的健康威胁。此外，疫苗可预防疾病的患病率不断上升，患者人数不断增加，推动了市场需求。政府旨在扩大疫苗接种计划的举措，特别是在中低收入国家，也促进了市场增长。随着这些进步，疫苗市场有望继续扩大，改善全球卫生状况，应对传染病带来的挑战。

疫苗市场规模

2023 年全球疫苗市场规模价值 748 亿美元，预计到 2031 年将达到 1686.9 亿美元，2024 年至 2031 年预测期内的复合年增长率为 10.70%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

疫苗市场趋势

“对创新疫苗接种解决方案的需求不断增加”

The global vaccine market is experiencing significant growth, fueled by the increasing demand for innovative vaccination solutions and a heightened focus on public health. One notable trend is the shift towards mRNA vaccine technology, which gained prominence during the COVID-19 pandemic with the successful deployment of vaccines like Pfizer-BioNTech and Moderna. Such technology allowed for rapid development and high efficacy rates and opened new avenues for addressing other infectious diseases, such as influenza and Zika virus, through similar platforms. Furthermore, the rise of combination vaccines is enhancing market dynamics, enabling healthcare providers to deliver immunizations for multiple diseases in a single dose, thereby improving patient adherence. The pentavalent vaccine, offering protection against five diseases, exemplifies this trend by fulfilling the need for broader immunization strategies. As public awareness and government support for vaccination initiatives continue to grow, the vaccine market is well-positioned to expand, contributing to improved health outcomes globally.

Report Scope and Vaccine Market Segmentation      

Vaccine Market Definition

Vaccines are biological preparations designed to provide immunity against specific infectious diseases. They typically contain weakened or inactivated forms of pathogens (such as viruses or bacteria), or components of these pathogens, such as proteins or sugars. When administered, vaccines stimulate the immune system to recognize and remember the pathogen, allowing the body to mount a faster and more effective response if exposed to the actual disease in the future. This process helps to prevent illness and reduce the spread of infectious diseases within communities. Vaccines can be delivered through various routes, including injections, oral formulations, and nasal sprays, and are a crucial component of public health strategies worldwide.

Vaccine Market Dynamics

Drivers

• Rising Incidence of Infectious Diseases

The rising global incidence of infectious diseases is a significant driver of vaccine demand. Recent outbreaks of illnesses such as measles, influenza, and COVID-19 have highlighted the essential role of vaccination in controlling the spread of infectious diseases and lessening their impact on public health. According to data from the World Health Organization (WHO) released in July 2023, coverage of the third dose of the diphtheria, tetanus, and pertussis (DTP3) vaccine increased from 81% in 2021 to 84% in 2022. In addition, the percentage of children receiving the first dose of the measles vaccine rose slightly from 81% in 2021 to 83% in 2022. These results reflect advancements in global vaccination efforts and a growing emphasis on immunization programs worldwide, further enhancing the vaccine market.

• Increased Funding for Vaccine Research

The increase in funding for vaccine research from government bodies and private organizations is driving the development of new vaccines and expanding the market. Project NextGen, initiated by the U.S. Department of Health and Human Services (HHS), aims to expedite and enhance the rapid development of next-generation vaccines and treatments through public-private partnerships, backed by an initial investment of USD 5 billion. This surge in funding is facilitating research efforts focused on a diverse range of diseases, including emerging infectious diseases and cancer. As a result, there is a strong pipeline of new vaccines that address unmet medical needs and stimulate market growth.

Opportunities

• Expansion of Vaccination Programs

Expansion of Vaccination Programs is significantly transforming the market, especially in developing countries where access to vaccines remains limited. According to the World Health Organization (WHO), data from various nations reveal that barriers and inequities in access to pediatric vaccines continue to exist, with the rotavirus vaccine being utilized in only 58% of self-procuring middle-income countries. Likewise, the human papillomavirus vaccine is administered in only 41% of lower-income countries, despite these nations facing a considerable burden from cervical cancer and having limited access to other preventive and curative healthcare services. Increasing investments in healthcare infrastructure and vaccination initiatives can enhance vaccine coverage and mitigate the impact of vaccine-preventable diseases in these regions, presenting a substantial market opportunity for vaccine manufacturers.

• Development of Next-Generation Vaccines

The emergence of next-generation vaccines, including mRNA and recombinant vaccines, offers significant opportunities for innovation and growth in the market. These vaccines provide benefits such as faster development timelines, enhanced efficacy, and improved safety profiles. The acquisition of Affinivax, Inc. by GSK plc illustrates the potential associated with next-generation vaccines in the market. Affinivax’s groundbreaking efforts in creating next-generation pneumococcal vaccines, such as AFX3772, highlight the capacity of these vaccines to deliver substantial improvements over traditional vaccine technologies. Companies like GSK are investing in the development of next-generation vaccines to address the evolving needs of healthcare systems worldwide, thereby creating new opportunities for growth and innovation in the vaccine sector.

Restraints/Challenges

• Involved Adverse Reactions and Side Effects

High development costs represent a significant challenge in the vaccines market, as the research and development (R&D) phase is often both expensive and time-consuming. For instance, developing a new vaccine can require billions of dollars and several years of research, which includes preclinical studies, clinical trials, and regulatory approvals. The development of the COVID-19 vaccines, where companies like Moderna and Pfizer invested heavily in R&D, often supported by government funding and partnerships. However, pharmaceutical companies targeting less profitable markets, such as vaccines for neglected tropical diseases, face additional financial risks. These markets often lack sufficient return on investment, leading to fewer companies willing to invest in the necessary research. Consequently, this financial burden can deter innovation and limit the availability of vaccines for diseases that predominantly affect low-income populations, thereby impacting global vaccines market.

• Cold Chain Requirements

Cold chain requirements present a significant market challenge in the vaccine distribution process, as many vaccines need to be stored and transported at specific temperature ranges to maintain their efficacy and safety, directly impacting market accessibility and effectiveness. For instance, vaccines like the Pfizer-BioNTech COVID-19 vaccine initially required ultra-low temperature storage at around -70 degrees Celsius (-94 degrees Fahrenheit), complicating logistics and limiting accessibility, particularly in low-resource settings where such infrastructure is often lacking. Such challenge is further exacerbated by the fact that even with more stable vaccines, maintaining the cold chain can be difficult due to power outages, inadequate refrigeration facilities, and transportation issues in remote areas. Consequently, these logistical hurdles can lead to vaccine spoilage, reduced supply, and increased costs, ultimately hampering vaccination efforts and limiting market growth potential.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Vaccine Market Scope

The market is segmented on the composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Composition

• Combination Vaccines
• Monovaccines

Type

• Subunit Vaccines
• Recombinant Vaccines
• Polysaccharide Vaccines
• Conjugate Vaccines
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• DNA Vaccines

Kind

• Routine Vaccine
• Recommended Vaccine
• Required Vaccine

Age of Administration

• Pediatric Vaccine
• Adult Vaccine

Diseases

• Pneumococcal Disease
• Measles
• Mumps and Varicella
• DPT (Diphtheria, Pertussis, and Tetanus)
• Hepatitis
• Influenza
• Typhoid
• Meningococcal
• Rabies
• Japanese Encephalitis
• Yellow Fever
• Others

Route of Administration

• Injectable
• Oral
• Nasal

End User

• Community Hospitals
• Hospitals
• Specialty Centres
• Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Vaccine Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the market, driven by its strong healthcare infrastructure and the presence of prominent industry players. The introduction of innovative vaccines, including those for rotavirus, pneumococcal conjugate, and human papillomavirus, presents significant opportunities for cost reduction and the establishment of new supply chains and distribution networks. Moreover, the region's investment in research and development, coupled with favorable government policies, further enhances the potential for growth in vaccine production and accessibility, ultimately benefiting public health initiatives across the continent.

预计亚太地区未来几年将经历大幅增长，这是因为患者人数不断增加，需要加强医疗服务。此外，对医疗基础设施和技术的投资增加将加强医疗服务的提供和获得医疗的机会。此外，强有力的政府支持和旨在改善公共卫生系统的举措可能会促进这个充满活力的地区医疗市场的整体发展和扩张。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

疫苗市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的疫苗市场领导者是：

• 默克公司（美国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 赛诺菲（法国）
• 印度血清研究所私人有限公司 (印度)
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Indian Immunologicals Ltd.（印度）
• Axplora（法国）
• 默克集团（德国）
• Charles River Laboratories（英国）
• uniQure NV (荷兰)
• Waisman Biomanufacturing（美国）
• Creative Biogene（美国）
• Aldevron LLC（美国）
• Addgene (美国)
• Oxford Biomedica PLC（英国）
• 赛默飞世尔科技公司（美国）
• 富士胶片株式会社（日本）
• Spark Therapeutics, Inc.（美国）

疫苗市场最新动态

• 2024 年 5 月，Novavax 和赛诺菲宣布达成一项共同独家许可协议，共同商业化一款 COVID-19 疫苗，并合作开发针对 COVID-19 和流感的创新联合疫苗。这一战略联盟使两家公司能够利用各自的专业知识和资源向市场提供先进的疫苗解决方案
• 2023 年 3 月，CSL Limited 在马萨诸塞州沃尔瑟姆开设了一家新的疫苗研发设施，旨在利用颠覆性技术（包括下一代 mRN）制造先进疫苗

SKU-53099